Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A randomized clinical trial of adjuvant chemotherapy with TS-1 versus UFT following curative operation for Stage III colorectal cancer

ABSTRACT: Interventions: UFT 400mg/m2/day 5days’ medication, 2days’ rest Start medication within 6weeks postoperatively, continue for 12months TS-1 80mg/m2/day 28days’ medication, 14days’ break Start medication within 6weeks postoperatively, continue for 12months Primary outcome(s): 3-year disease free survival Study Design: Parallel Randomized

DISEASE(S): Stage Iii Colorectal Cancer

PROVIDER: 2609743 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase 1 Trial of Lonsurf with Irinotecan and Bevacizumab in Patients with Unresectable Metastatic Colorectal Cancer(mCRC).

Project description:Interventions: 1 cycle is 28days. Lonsurf(25mg/m2)is administered orally twice daily in 1-5days and 8-12 days. Irinotecan(100mg/m2) and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): Recommended dose:RD Study Design: Single arm Non-randomized

| 2634299 | ecrin-mdr-crc

Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

| 2641267 | ecrin-mdr-crc

TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2646936 | ecrin-mdr-crc

Phase 1 Trial of Lonsurf with Irinotecan and Bevacizumab

| 2615622 | ecrin-mdr-crc

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Project description:Interventions: 1 cycle is 28days. TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 8-12 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): 4 month progression free survival by central assessment( 4M PFS) Study Design: Single arm Non-randomized

| 2628236 | ecrin-mdr-crc

Whole Blood Gene Expression Profiling in Patients Undergoing Laparoscopic Colon Cancer Surgery

Project description:We performed whole blood gene expression profiling in 26 patients undergoing laparoscopic surgery for colon cancer stage I-III UICC. Saples were taken the day before surgery (-1), day one postoperatively (+1) and day 10 postoperatively (+10). The aim of the study was to investigate whether gene expression was altered after laparoscopic colon cancer surgery.

2021-11-01 | GSE122626 | GEO

Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Project description:Interventions: 1 cycle is 28days. Nintedanib (150mg or 200mg) is orally administered twice daily and TAS-102 (35mg/m2) is orally administered twice daily in 1-5days and 8-12 days Primary outcome(s): 16 weeks progression free survival rate ( 16W PFS rate) Study Design: Single arm Non-randomized

| 2632430 | ecrin-mdr-crc

Bioequivalence study to compare Xeloda and Capecitabine tablets in patients with colorectal cancer or breast cancer

Project description:Intervention1: Capecitabine (CJSC Biocad) tablets 500mg: The study will involve patients who receive capecitabine monotherapy. In a monotherapy regimen, capecitabine is administered 1250 mg/m2 twice a day in the morning and evening (total daily dose of 2500 mg/m2) for two weeks followed by 7 days break. Within this study, Capecitabine will be administered orally in the morning of Day 1/Day 2 in the dose of 1250 mg/m2. The drug will be taken within 30 minutes after the meal (breakfast). Control Intervention1: Xeloda (Capecitabine)tablets 500mg: The study will involve patients who receive capecitabine monotherapy. In a monotherapy regimen, capecitabine is administered 1250 mg/m2 twice a day in the morning and evening (total daily dose of 2500 mg/m2) for two weeks followed by 7 days break. Within this study, Xeloda will be administered orally in the morning of Day 1/Day 2 in the dose of 1250 mg/m2. The drug will be taken within 30 minutes after the meal (breakfast). Primary outcome(s): Assessment of pharmacokinetic parameters after single administration of the Test drug and the reference drug: Area under capecitabine Â«concentration-timeÂ» curve at the time of the drug administration up to 12 hours (AUC(0-12)) Timepoint: 0 min, 15 mins, 30 mins, 45 mins, 1hr, 1hr 30 mins, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 8 hrs, 10 hrs and 12 hrs after administration of the test or reference drug. Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Open Label

| 2574596 | ecrin-mdr-crc

A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancer

Project description:Interventions: UFT(300mg/m2/day) and LV(75mg/day) are simultaneously given 3times per day for 5days, followed by 2-day rest. Bevacizumab is administerd by every 3 weeks. Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2639580 | ecrin-mdr-crc

Expression data throughout reprogramming of MEF to iPS using a Dox-inducible promoter

Project description:6C secondary MEFs were treated with Dox in mES media to turn on the Oct4, Klf4, cMyc, Sox2. Total RNA was extracted at day 0 (no Dox), day2, 5, 8, 11, 16 and 21 (with Dox) and day 30 (Dox-independent secondary iPS). RNA from Parental MEFs and Primary-iPS cells were also extracted for reference. 1B secondary MEFs were Dox treated for 5-days followed by RNA extraction. Subsequently, a culture removed of Dox treatment for an additional 5days was also analyzed.

2010-07-01 | GSE21757 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data